Keyword: Stivarga

Bristol-Myers Squibb is out to expand the pool of colorectal cancer patients it can treat with Opdivo—and it’s bringing in Bayer to help.

In a head-to-head against Bayer's Nexavar, Opdivo failed to significantly extend patients' lives in newly diagnosed liver cancer patients.

Despite a veritable graveyard of drug prospects in hard-to-treat glioblastoma, Bayer hopes underperforming Stivarga can crack the code in new trials.

With angry investors and thousands of lawsuits bearing down, Bayer is scrambling to keep its head above water. Looks like relief isn’t coming soon.

After Eli Lilly’s Cyramza flopped a liver cancer trial five years ago, the drugmaker’s chances in the field looked slim. That all changed Monday.

China sales and older meds helped boost Bayer's pharma results, but those numbers couldn't eclipse concerns about mushrooming Monsanto litigation.

Exelixis nabbed an FDA nod for Cabometyx in second-line liver cancer, where Stivarga, Opdivo and Keytruda are already battling it out.

Merck just advanced the Keytruda-Opdivo immuno-oncology rivalry into a brand-new arena.

Seventeen cancer drugs from global and local drugmakers take an average 56.7% discount to win spots on China's insurance scheme.

China, which has been waving through cancer drugs made by multinational pharmas, can now count a homegrown one among its approvals.